Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer

被引：0
|
作者：
Novello, Silvia [1 ]
Rudell, Katja [2 ]
Bodnar, Carolyn [2 ]
Vowler, Sarah [2 ]
Rupnik, Tina [3 ]
Ghiorghiu, Serban [2 ]
机构：
[1] Univ Turin, Dept Oncol, Turin, Italy
[2] Astrazeneca, Cambridge, England
[3] Phastar, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
osimertinib; symptoms; Non-small-cell lung cancer; Patient-reported outcomes;
D O I：
10.1016/j.jtho.2016.11.1747
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-080
引用
收藏
页码：S1238 / S1239
页数：2
相关论文
共 50 条
  • [21] IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer
    Tang, Xiaonan
    Mu, Jing
    Ma, Li
    Tan, Qifan
    Wang, Jinghui
    Tan, Jinjing
    Zhang, Shucai
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 571 : 38 - 45
  • [22] Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.
    Giallombardo, Marco
    Chacartegui, Jorge Jorge
    Reclusa, Pablo
    Van Meerbeeck, Jan P.
    Alessandro, Riccardo
    Peeters, Marc
    Pauwels, Patrick
    Rolfo, Christian Diego
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
    Ham, Jun Soo
    Kim, Seokhwi
    Kim, Hee Kyung
    Byeon, Seonggyu
    Sun, Jong-Mu
    Lee, Se-hoon
    Ahn, Jin Seok
    Park, Keunchil
    Choi, Yoon-La
    Han, Joungho
    Park, Woongyang
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) : E1 - E4
  • [24] Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non-small cell lung cancer cells
    Twum, Yaw
    Marshall, Kent
    Gao, Weimin
    BIOFACTORS, 2023, 49 (06) : 1143 - 1157
  • [25] AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials
    Gil-Bazo, Ignacio
    Rolfo, Christian
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 85 - 88
  • [26] Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291 br
    Wang, Zhen
    Lei, Panpan
    Li, Ziyang
    Han, Xiao
    Yang, Fei
    Su, Tian
    Meng, Caiting
    Hou, Zhanwu
    Liu, Huadong
    ACS CHEMICAL BIOLOGY, 2022, 17 (10) : 2849 - 2862
  • [27] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
  • [28] Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy
    Wang, Xin Shelley
    Shi, Qiuling
    Williams, Loretta A.
    Komaki, Ritsuko
    Gomez, Daniel R.
    Lin, Steven H.
    Chang, Joe Y.
    O'Reilly, Michael S.
    Bokhari, Raza H.
    Cox, James D.
    Mohan, Radhe
    Cleeland, Charles S.
    Liao, Zhongxing
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (05) : 832 - 838
  • [29] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 113 - 125
  • [30] Patient-reported outcomes and quality of life in advanced ALK plus non-small-cell lung cancer trial of brigatinib (ALTA)
    Lenderking, William R.
    Lin, Huamao
    Speck, Rebecca M.
    Zhu, Yanyan
    Huang, Hui
    Huang, Joice
    Kerstein, David
    Langer, Corey J.
    FUTURE ONCOLOGY, 2019, 15 (24) : 2841 - 2855
12345